Insulet (NSDQ:PODD) said today that its Omnipod device was selected as the preferred insulin pump in British Columbia, Canada under the province’s expanded PharmaCare insulin pump program.
According to the terms of the program, any eligible individual who requests an initial or replacement insulin pump will receive coverage for the Billerica, Mass.-based company’s device.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet’s Omnipod nabs preferred insulin pump status in British Columbia appeared first on MassDevice.